Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05113355
Other study ID # HS-3197D
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 17, 2021
Est. completion date November 15, 2024

Study information

Verified date October 2021
Source Peking Union Medical College Hospital
Contact Chunmei Bai, M.D.
Phone 69158706
Email baichunmei1964@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the efficacy and safety of chidamide combined with sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm.


Description:

This study is a single-arm, multi-center, two-stage, phase II clinical trial conducted in China. This study adopts Simon's two-stage design, and the inclusion criteria and exclusion criteria of the two stages were consistent. Six patients with high-grade neuroendocrine neoplasm will be enrolled in the first stage. If more than one complete or partial responses were seen at planned interim analysis, the additional 17 patients will be recruited in the second stage and a total of 23 patients will be treated.


Recruitment information / eligibility

Status Recruiting
Enrollment 23
Est. completion date November 15, 2024
Est. primary completion date November 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years; 2. Histologically confirmed advanced and metastatic high-grade neuroendocrine neoplasm; 3. Receive = 2 types of chemotherapy for high-grade neuroendocrine tumors and had tumor progression; 4. ECOG = 2; 5. Have at least one measurable lesion according to RECIST version 1.1; 6. Absolute neutrophil count = 1.5×109 / L, platelet count = 100×109 / L, hemoglobin = 90 g/L; 7. Provide tumor samples for pathological diagnosis and PD-L1 biomarker detection; 8. Have ability to sign a written informed consent. Exclusion Criteria: 1. Small cell lung cancer; 2. Have surgery or trauma within 4 weeks before enrollment, or are expected to receive surgical treatment; 3. Previous use of HDAC inhibitors; 4. Previous use of PD-1/PD-L1/PD-L2/CTLA-4 inhibitors; 5. Allergy to related drug components; 6. Have a medical history of immune deficiency diseases, or organ transplantation; 7. Have active autoimmune diseases requiring treatment or a medical history of autoimmune diseases in the past 2 years; 8. Have uncontrolled or significant cardiovascular disease; 9. Abnormal liver function (total bilirubin > 1.5×upper limit of normal); Transaminases (ALT/AST) >2.5×upper limit of normal (>5x upper limit of normal for patients with liver metastases), abnormal renal function (serum creatinine > 1.5×upper limit of normal); 10. Pregnancy ; 11. Receive any live or live attenuated vaccine within 4 weeks before enrollment; 12. Have serious diseases that may endanger the safety of patients, or affect patients to complete the research; 13. Any serious mental or cognitive disorder; 14. Patients are currently enrolled in another drug clinical trial within 4 weeks prior to enrollment; 15. Any other condition which is inappropriate for the study in the opinion of the investigators.

Study Design


Intervention

Drug:
Chidamide
30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
Sintilimab
200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.

Locations

Country Name City State
China Harbin Medical University Cancer Hospital Harbin Heilongjiang
China The First Affiliated Hospital of Xiamen University Xiamen Fujian

Sponsors (3)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Harbin Medical University, The First Affiliated Hospital of Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) Percentage of participants with complete response and partial response, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 Up to 2 years
Secondary Disease Control Rate (DCR) Percentage of participants with complete response, partial response, and stable disease assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 Up to 2 years
Secondary Progression-free Survival (PFS) Time from the date of enrollment until progression or death, whichever is first met Time from the date of enrollment to the earliest of documented disease progression or death, assessed up to 2 years
Secondary Overall Survival (OS) Time from the date of enrollment until death Time from the date of enrollment to the earliest of documented death, assessed up to 3 years
Secondary Treatment-related Adverse Events (Safety) Frequency and grade of adverse events (the grade of adverse events is assessed according to CTCAE v4.03) Up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT02815969 - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Completed NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Phase 2
Completed NCT02134639 - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation N/A
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Terminated NCT01163526 - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies N/A
Completed NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors N/A
Completed NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase 3
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Active, not recruiting NCT04544098 - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Early Phase 1
Active, not recruiting NCT02736500 - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Phase 1/Phase 2